PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced that Phase 2 clinical data for D-PLEX₁₀₀ will be presented at the European Society for Coloproctology Scientific Conference from September 21-23, 2022, in Dublin, Ireland. The lead candidate D-PLEX₁₀₀ is designed to prevent surgical site infections through a controlled release of doxycycline for 30 days. The presentation, by Dr. Anthony J. Senagore, aims to highlight the product's potential in improving surgical outcomes.

Positive

• D-PLEX₁₀₀ shows promise in preventing surgical site infections.
• Presentation at a prominent European conference may enhance visibility and credibility.

Negative

• None.

Efficacy Data of D-PLEX₁₀₀ in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation

PETACH TIKVA, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX₁₀₀ will be highlighted in a podium presentation at the European Society for Coloproctology (ESCP) Scientific Conference to be held on September 21-23, 2022, in Dublin, Ireland.

European Society for Coloproctology Scientific Conference:

Title:	D-PLEX100, a novel doxycycline formulation that provides high, local concentrations of antibiotic activity for 30 days to reduce surgical site infections
Presenter:	Anthony J. Senagore, M.D., Senior Medical Director, PolyPid
Date:	Wednesday, September 21, 2022, part of the Modern Colorectal Surgeon session

The abstract will be available on  www.polypid.com/publications/ following the presentation.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts: 
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

 

FAQ

What is the purpose of the D-PLEX100 clinical trial?

The clinical trial aims to evaluate the efficacy of D-PLEX100 in preventing surgical site infections after abdominal surgery.

When will the D-PLEX100 data be presented?

The data will be presented at the European Society for Coloproctology Scientific Conference from September 21-23, 2022.

Who will present the D-PLEX100 data?

Dr. Anthony J. Senagore, Senior Medical Director at PolyPid, will present the data.

How long does D-PLEX100 provide antibiotic activity?

D-PLEX100 provides local concentrations of antibiotic activity for up to 30 days.

What is the significance of the D-PLEX100 Phase 2 results?

The Phase 2 results will help determine the potential effectiveness of D-PLEX100 in reducing surgical site infections, influencing future clinical development.